| This week's sponsor is ICON. | |  | ICON Functional Solutions
An economical delivery model that evolves with your needs with benefits beyond costs savings: - improved strategic flexibility
- innovation
- ease of management.
Read More.
|
Featured Story | Tuesday, April 25, 2017  After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss conference in mid-June, the Big Pharma has confirmed to FierceBiotech that it will indeed be posting the long-awaited data.
|
|
|
| This week's sponsor is UPS. | |  | The Temperature-Sensitive Packaging Breakdown
A survey was conducted to understand the healthcare manufacturers' efforts in developing cold-chain packaging-and the results were revealing. Take the short quiz to see how informed you are when it comes to temperature-controlled shipping. |
Top Stories | Tuesday, April 25, 2017 It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the biotech will shed 50% of its workforce. |
|
|
| Tuesday, April 25, 2017 Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets. The Series B round continues the rapid rise of Sienna, which has raised $74 million and bought Creabilis since it emerged helmed by the ex-Kythera Biopharmaceuticals team last year. |
|
|
Monday, April 24, 2017 It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses that give us the energy we need for all our vital functions. | Tuesday, April 25, 2017 Circassia CEO Steve Harris has defended the running of the company’s allergy trials, stating nothing could have been done better. Harris made the comments after presenting annual results that mark another step in the transition of Circassia away from its original area of focus. |
|
|
| Tuesday, April 25, 2017 Novartis will play a bigger role in the marketing of migraine drug erenumab—thanks to a reworking of its 2015 commercialization deal with Amgen—but analysts say the move may reflect reduced sales expectations. |
|
|
| Tuesday, April 25, 2017 Two Pore Guys closed a $24.5 million Series A round, which will boost the manufacturing of the company’s handheld testing system, as well as further develop its nanopore technology for whole genome sequencing and genome mapping. |
|
|
| Tuesday, April 25, 2017 After raising $31 million just last year, California-based clinical research company Science 37 has now served up a Series C round worth $29 million. Glynn Capital Management led the cash boost with help from Google’s venture firm GV, as Science 37 plots scaling up its operations and expanding around the globe. |
|
|
| Monday, April 24, 2017 Hoping to win over careful payers, Biogen has new data to support its superpricey spinal muscular atrophy (SMA) drug Spinraza. |
|
|
| This week's sponsor is J.P. Morgan Private Bank. | |  | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | Bispecific-focused China biotech EpimAb Biotherapeutics has raised $25 million in its Series A funding round. Statement Neurodegenerative disease and RNA biotech Aquinnah Pharmaceuticals has been given a $10 million investment boost from Pfizer and AbbVie. Release DelMar Pharmaceuticals has penned a new, three-year collaboration with Duke University for VAL-083 in an aggressive form of brain cancer. Statement | |
|
Resources Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
